TSI’s manufacturing license for HMB approved in China

8b3549eb-fd9d-477a-a822-a79fbc3f5980articleimage.jpg

21 Aug 2017 --- TSI Group (TSI) has announced the approval of the first and only CFDA (China Food and Drug Administration) Manufacturing License for beta-hydroxy-beta-methylbutyrate (HMB) production in China. TSI’s Jiangyin Pharmaceutical facility, a wholly owned TSI Group company, received this exclusive license to produce HMB for use in Chinese food products.

Additionally, CFDA approved TSI’s HMB for an expanded range of Novel Food categories, such as beverages, chocolates, candies and baked goods. This approval is in addition to the existing and approved Chinese HMB markets; Sports Nutrition and Foods for Special Medical Purpose (FSMP, or Medical Foods).

“With the two new approvals, TSI is effectively positioned as the market leader and the only HMB manufacturer in China authorized to both produce and sell HMB ingredients domestically to the Chinese food and functional food markets and ultimately to deliver on our mission of promoting muscle health and to enhance consumers’ active lifestyles in China and around the world,” Alisan Sullivan, Senior Brand and Operations Manager, Innovative Products Division at TSI USA Inc., tells NutritionInsight.

TSI states that China is a key market for its global muscle health growth strategy and its mission is to deliver muscle health benefits that enhance and maintain consumers’ healthy and active lifestyles.

“After nearly two decades in the market and supported by a vast body of efficacy data (over 50 published clinical studies), HMB is a well-known and established staple for a sports enthusiast in the US and in Europe. With the sports nutrition market growing at 9 to 12 percent globally, and faster growth rates within the emerging economies like China, we see a great potential for our broad portfolio of HMB-based innovative and proprietary ingredients,” says Sullivan.

“Similarly, the general consumer awareness for HMB is growing fast, propelled by flagship products promoting muscle health and active lifestyle for elderly,” she adds.

“These recent regulatory approvals are significant milestones for all of us at TSI, the door is now wide open for us to deliver TSI’s world class HMB products to one of the fastest growing markets in the world – China,” concludes Larry Kolb, President, TSI Group. “We know HMB can make a difference in people’s daily lives and are excited for the opportunity to positively impact muscle health for millions of Chinese consumers – from athletes of all kinds to aging adults.”

By Paul Creasy

Related Articles

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

Food Ingredients News

Ingredia presents milk proteins in shelf-stable and high protein snacking concepts

05 Dec 2017 --- Consumers around the world are increasingly interested in achieving wellness through a healthy diet. To meet this mainstream trend, food and dairy producers continue to reduce fat content while increasing the protein amount in their products. At this year's FiE, Ingredia were presenting healthy, convenient and indulgent products with their PROMILK 600 A and PROMILK SH 20 dairy ingredients.

Nutrition & Health News

Demand for Advanced Lipids’ infant formula solution soars as tenth anniversary marked

04 Dec 2017 --- Demand for infant formula containing Infat SN-2 palmitate – an ingredient that mimics the fatty acid profile in human milk – has soared over the past decade and will continue to grow, according to Advanced Lipids. The company, a joint venture between Enzymotec and AAK, is celebrating its tenth anniversary this year.

Food Research

Cardiovascular risk in diabetes can be reduced using hormones, claims study

04 Dec 2017 --- Scientists at Joslin Diabetes Center in the US have taken another step toward solving a long-standing puzzle about heart health in Type 2 diabetes, with a finding that eventually may point towards more personalized patient care. Genetic analysis has linked the hormone known as glucagon-like peptide 1 (GLP-1) with cardiovascular mortality risks.

Nutrition & Health News

NattoPharma enters Chinese market with new MenaQ7 launch

30 Nov 2017 --- NattoPharma has participated in a launching conference commemorating the first product introduced in China featuring MenaQ7 Vitamin K2 as MK-7. During the event, FishBurg, a Chinese dietary supplement producer in the calcium/vitamin D3 (VD3) segment, signed a partnership and supply agreement with NattoPharma and officially launched its new Blue Hat-registered calcium/VD3/MenaQ7 Vitamin K2 supplement for bone health to the Chinese market.

More Articles
URL : http://www.nutritioninsight.com:80/news/tsis-manufacturing-license-for-hmb-approved-in-china.html